VERX - Vertex, Inc.
KING OF PRUSSIA, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), the Decision-to-Defense™ global indirect tax and compliance company, today announced that it will release third quarter 2026 financial results after the market close on Wednesday, November 4, 2026.
Thanks to its most recent acquisition, Vertex now has some promising products in the field of hormone disorders. These could eventually become meaningful growth drivers for the company.
KING OF PRUSSIA, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), the Decision-to-Defense™ global indirect tax and compliance company and an Oracle partner, today announced that its enterprise tax determination engine, Vertex O Series Tax Engine for Oracle, has achieved Oracle Validated: Oracle Cloud Infrastructure Expertise and is now available in the Oracle Marketplace, offering added value to Oracle Cloud customers.
Latigo Biotherapeutics is undervalued below IPO, with onzotrigine showing superior efficacy to Vertex's Journavx in acute pain. LTGO leverages Vertex's market groundwork, has pivotal-eligible Phase 2 data, and is funded into 2029, reducing near-term financing risk. Onzotrigine's Phase 3 bunionectomy trial is the key binary event; positive results could drive significant upside versus current market expectations.
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversib.
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2026 financial results on Monday, November 2, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Third Quarter 2026 Earnings Call.” The conference call will be webcast live and a link to the webcast ca.
Axsome Therapeutics is delivering explosive revenue growth as it scales its commercial portfolio for central nervous system disorders. Vertex Pharmaceuticals remains a highly profitable giant with absolute dominance in cystic fibrosis and expanding reach in gene therapy.
KING OF PRUSSIA, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), the Decision-to-Defense™ global indirect tax and compliance company, today announced the appointment of Debanjan Saha to its Board of Directors, effective October 7, 2026.
Vertex Pharmaceuticals is the leader in the cystic fibrosis market and has the intellectual property to maintain this dominance. The company has expanded into additional treatment areas and is awaiting a regulatory decision for another potential new product in the coming weeks.
Corient Private Wealth LP purchased a new position in Vertex, Inc. (NASDAQ: VERX) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 153,840 shares of the company's stock, valued at approximately $1,766,000. Corient Private Wealth LP owned about 0.09% of Vertex
CRISPR Therapeutics is transitioning into a commercial-stage company with its pioneering gene-editing treatment, CASGEVY. Vertex Pharmaceuticals maintains a dominant, highly profitable position in the global cystic fibrosis market.
VRTX announces positive AMPLIFIED data for inaxaplin, while completing AMPLITUDE enrollment and targeting interim results in early 2027.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Tuesday reported data from its Phase 2b AMPLIFIED trial evaluating inaxaplin in individuals with APOL1-mediated kidney disease (AMKD).
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease (AMKD) and modest proteinuria and in people with AMKD and type 2 diabetes. In this study, inaxaplin was evaluated as a 45 mg once-daily dose on top of optimized standard of care. Forty-one people were enrolled and dosed in two cohorts: 1) people with AMKD with modest proteinuria (UACR ≥0.1 g/g to.
AbbVie is profitable, growing, and paying a rising dividend. CRISPR is burning cash in pursuit of a gene-editing breakthrough that could reshape medicine.
Vertex Pharmaceuticals NASDAQ: VRTX is continuing to broaden its business beyond cystic fibrosis, with its renal medicine portfolio, rare endocrine assets and cell therapies among the company's priorities, CEO and President Reshma Kewalramani said at Morgan Stanley's 24th Annual Healthcare Conference.
Vertex Pharmaceuticals NASDAQ: VRTX highlighted a series of upcoming clinical, regulatory and commercial catalysts across renal disease, pain management, cystic fibrosis and endocrinology during a Wells Fargo healthcare conference appearance.
Vertex Pharmaceuticals NASDAQ: VRTX outlined a broadening commercial and clinical strategy at the Cantor Global Healthcare Conference, highlighting its recent Crinetics acquisition, planned renal product launch efforts and upcoming pipeline milestones across kidney disease, pain, cystic fibrosis and rare endocrine disorders.
One company is scaling revenue rapidly but burning cash; the other is pioneering gene therapy with minimal sales and massive losses.
Since 2008, Vertex Pharmaceuticals, Inc. (VRTX) shares have received 42 outlier institutional inflow signals and gained over 1,682%.